PMID- 10759766
OWN - NLM
STAT- MEDLINE
DCOM- 20000508
LR  - 20190513
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 120
IP  - 1
DP  - 2000 Apr
TI  - Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant 
      protein-1 (MCP-1) expression by stimulated vascular endothelial cells.
PG  - 71-8
AB  - In a previous study, it was reported that stimulation with a TXA2 receptor 
      agonist, U46619, augments the expression of adhesion molecules by human umbilical 
      vein endothelial cells (HUVEC). In the present study we showed that U46619 
      augments the expression of MCP-1 in HUVEC, both at the protein and mRNA levels. 
      Pretreatment with TXA2 receptor antagonists greatly diminishes the extent of 
      tumour necrosis factor-alpha (TNF-alpha)-, platelet-activating factor (PAF)-, or 
      U46619-induced mRNA accumulation and production of MCP-1. Protein kinase C (PKC) 
      inhibitors diminish U46619-induced mRNA accumulation and production of MCP-1. 
      NAC, which inhibits nuclear factor kappaB (NF-kappaB) activation and activating 
      protein 1 (AP-1) binding activity, inhibits the expression of MCP-1 at the 
      protein and mRNA levels. These results indicate that in HUVEC stimulation via the 
      TXA2 receptors augments MCP-1 production by induction of the NF-kappaB and AP-1 
      binding activity through the PKC system.
FAU - Ishizuka, T
AU  - Ishizuka T
AD  - Division of Biomedical Engineering, National Defence Medical College Research 
      Institute, Tokorozawa, Saitama, and Bayer Yakuhin Ltd, Osaka, Japan.
FAU - Sawada, S
AU  - Sawada S
FAU - Sugama, K
AU  - Sugama K
FAU - Kurita, A
AU  - Kurita A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Chemokine CCL2)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Thromboxane)
RN  - 0 (Transcription Factors)
RN  - 0 (Vasoconstrictor Agents)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid)
RN  - EC 2.7.11.13 (Protein Kinase C)
SB  - IM
MH  - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology
MH  - Cells, Cultured
MH  - Chemokine CCL2/*antagonists & inhibitors/*biosynthesis
MH  - Endothelium, Vascular/*cytology/drug effects/*metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Humans
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - Protein Kinase C/antagonists & inhibitors
MH  - RNA, Messenger/biosynthesis/metabolism
MH  - Receptors, Thromboxane/*antagonists & inhibitors
MH  - Thromboxane A2/*metabolism
MH  - Transcription Factors/antagonists & inhibitors
MH  - Umbilical Veins
MH  - Vasoconstrictor Agents/pharmacology
PMC - PMC1905609
EDAT- 2000/04/12 09:00
MHDA- 2000/05/16 09:00
PMCR- 2001/04/01
CRDT- 2000/04/12 09:00
PHST- 2000/04/12 09:00 [pubmed]
PHST- 2000/05/16 09:00 [medline]
PHST- 2000/04/12 09:00 [entrez]
PHST- 2001/04/01 00:00 [pmc-release]
AID - cei1169 [pii]
AID - 10.1046/j.1365-2249.2000.01169.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2000 Apr;120(1):71-8. doi: 10.1046/j.1365-2249.2000.01169.x.